United Statesbtc

Artiva Biotherapeutics (NASDAQ:ARTV) has reached a pivotal regulatory milestone, securing FDA alignment for a single Phase 3 registrational trial of its lead candidate, AlloNK, following positive initial data in refractory rheumatoid arthritis (RA).

ANI Pharmaceuticals (NASDAQ:ANIP) delivered a robust first-quarter performance for 2026, fueled by the continued rapid expansion of its Rare Disease segment.

BioArctic announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi Iqlik (lecanemab-irmb).

Gilead Sciences (NASDAQ:GILD) delivered a steady first quarter for 2026, as the company’s core HIV business and expanding oncology franchise provided a solid buffer against the continued normalization of pandemic-related product sales.

BioRestorative Therapies (NASDAQ:BRTX) announced significant clinical progress in its lead cell therapy program, BRTX-100, reporting expanded blinded Phase 2 data that demonstrates long-term efficacy for patients suffering from chronic lumbar disc disease (cLDD).

Scholar Rock (NASDAQ:SRRK) reported first-quarter 2026 financial results that underscore a period of heavy investment as the company transitions toward potential commercialization of its lead muscle-targeted therapies.

Becton, Dickinson and Company (NYSE:BDX), commonly known as BD, reported steady growth for its fiscal second quarter of 2026, marking its first full period of operations following a transformative structural reset.

Oculis Holding (NASDAQ:OCS) has received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for its Phase 3 PIONEER-1 trial.

Argenx (NASDAQ:ARGX) delivered a powerful start to 2026, reporting first-quarter financial results that demonstrate the accelerating commercial scale of its flagship FcRn blocker, VYVGART.

Pharming Group (NASDAQ:PHAR) reported first-quarter 2026 results that reflect a strategic transition toward its new growth engine, Joenja, while navigating anticipated headwinds in its legacy portfolio.